^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
New
Title:

Optimal therapy for concomitant EGFR and TP53 mutated non-small cell lung cancer: A real- world study

Published date:
11/30/2022
Excerpt:
The present study aims to compare the benefits of EGFR-TKIs and its combination with antiangiogenic drugs or chemotherapy in patients with NSCLC harboring EGFR and TP53 co-mutation in a real-life setting....Combination therapy had a higher efficacy than EGFR-TKI alone for patients with NSCLC having concomitant EGFR and TP53 mutation.
DOI:
https://doi.org/10.21203/rs.3.rs-2247421/v1